{
    "cancer_info": {
        "cancer_name": "Bone Cancer"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "MRI with or without contrast (primary site)",
            "CT with contrast (primary site)",
            "Chest CT",
            "Whole-body PET-CT",
            "Bone scan",
            "Plain radiographs",
            "Core needle biopsy",
            "Open biopsy",
            "Bone marrow biopsy (Ewing sarcoma)",
            "CBC",
            "Comprehensive metabolic panel (CMP) with calcium",
            "LDH test",
            "Alkaline phosphatase (ALP) test",
            "Serum protein electrophoresis (SPEP)",
            "Molecular testing for EWSR1-ETS fusions",
            "IDH1/IDH2 mutation testing",
            "SMARCB1 testing (poorly differentiated chordoma)",
            "Comprehensive Genomic Profiling (CGP)",
            "Fertility consultation (AYA patients)",
            "Genetic counseling/testing (family history)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Chondrosarcoma - Low-grade",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Extremity tumors",
                    "plan_name": "Intralesional excision",
                    "plan_details": "± cryotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard"
                },
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Pelvic tumors",
                    "plan_name": "Wide excision",
                    "plan_details": "With negative margins",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "Chondrosarcoma - High-grade/Unresectable",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary treatment",
                    "patient_subgroup": "Skull base/axial tumors",
                    "plan_name": "Proton/carbon ion RT",
                    "plan_details": "70 Gy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Option"
                },
                {
                    "treatment_line": "Advanced treatment",
                    "patient_subgroup": "IDH1-mutated",
                    "plan_name": "Vosidenib",
                    "plan_details": "IDH1 inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Ewing Sarcoma - Localized",
            "risk_group": "Standard risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "VDC/IE regimen",
                    "plan_details": "Vincristine/Doxorubicin/Cyclophosphamide alternating with Ifosfamide/Etoposide × 6 cycles",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Local control",
                    "patient_subgroup": "Resectable tumors",
                    "plan_name": "Surgery ± RT",
                    "plan_details": "55.8 Gy boost for positive margins",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Ewing Sarcoma - Metastatic",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Pulmonary metastases",
                    "plan_name": "Chemo + SBRT/surgery",
                    "plan_details": "Stereotactic body radiotherapy or metastasectomy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Option"
                },
                {
                    "treatment_line": "Relapsed treatment",
                    "patient_subgroup": "Refractory disease",
                    "plan_name": "Cabozantinib",
                    "plan_details": "VEGFR2/MET inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Osteosarcoma - Localized",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "Patients <40 years",
                    "plan_name": "MAP regimen",
                    "plan_details": "Methotrexate (high-dose) + Cisplatin + Doxorubicin",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Surgical intervention",
                    "patient_subgroup": "All patients",
                    "plan_name": "Wide excision",
                    "plan_details": "Limb-sparing surgery with negative margins",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Standard"
                }
            ]
        },
        {
            "staging_criteria": "Osteosarcoma - Metastatic/Relapsed",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line treatment",
                    "patient_subgroup": "Refractory disease",
                    "plan_name": "Regorafenib",
                    "plan_details": "Multikinase inhibitor",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Palliative treatment",
                    "patient_subgroup": "Bone metastases",
                    "plan_name": "Samarium-153 EDTMP",
                    "plan_details": "Radiopharmaceutical for pain control",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Option"
                }
            ]
        },
        {
            "staging_criteria": "GCTB - Unresectable/Metastatic",
            "risk_group": "",
            "treatment_plans": [
                {
                    "treatment_line": "First-line treatment",
                    "patient_subgroup": "All patients",
                    "plan_name": "Denosumab",
                    "plan_details": "RANKL inhibitor",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Local control",
                    "patient_subgroup": "Inoperable lesions",
                    "plan_name": "Radiotherapy",
                    "plan_details": "40-50 Gy",
                    "nccn_evidence_category": "Category 2B",
                    "nccn_recommendation_category": "Last resort"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "IDH1/IDH2 mutations: Targetable with vosidenib in chondrosarcoma; EWSR1-ETS fusions: Diagnostic for Ewing sarcoma, prognostic impact dependent on fusion type; Serum LDH >300 U/L: Poor prognostic factor in Ewing sarcoma (HR: 2.1 for relapse); Histologic response (>90% necrosis): Strongest predictor of favorable outcome in osteosarcoma; SMARCB1 loss: Defines aggressive poorly differentiated chordoma; RANK/RANKL pathway: Denosumab target in GCTB; PDGFR/EGFR/mTOR pathways: Therapeutic targets in chordoma; MSI-H/dMMR or TMB-H (≥10 muts/Mb): Predictive for immune checkpoint inhibitors in advanced bone cancers"
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：骨癌.txt"
}